ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Development of a prediction model for cognitive impairment of sarcopenia using multimodal neuroimaging in non-demented older adults.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review and Meta-analysis on the association between sarcopenia and cognitive impairment in middle-aged and older adults from Latin America.The journal of nutrition, health & aging · 2026Pooled it
- Sarcopenia in cognitive disorders: Toward a shared pathophysiological framework.Osteoporosis and sarcopenia · 2026Review
- Impact of appendicular skeletal muscle mass on Alzheimer's disease in relation to age and comorbidities: an 8-year longitudinal follow-up study of a nationwide cohort.Alzheimer's research & therapy · 2026Article
- Soluble and plaque amyloid associations with peripheral glucose dysregulation modulated by tau pathology in Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Observational
- Systemic proteomic and organ aging signatures associated with plasma Aβ oligomerization in a Korean cohort: a cross-sectional study.Frontiers in aging neuroscience · 2026Article
- Imaging Biomarkers of Cognitive Impairment in Sarcopenia: A Narrative Review.International journal of general medicine · 2026Review
- Effectiveness of a Karaoke-Based Digital Therapeutic in Mild Cognitive Impairment: A Randomized, 12-Week Pilot Trial.Psychiatry investigation · 2025Article
- Can Myokines Serve as Supporters of Muscle-Brain Connectivity in Obesity and Type 2 Diabetes? Potential of Exercise and Nutrition Interventions.Nutrients · 2025Review
- Differential effects of soluble and plaque amyloid on late-life depression: The moderating role of tau pathology.The journal of prevention of Alzheimer's disease · 2025Article
- Temporal Muscle Thickness as a New Biomarker: Its Association With Alzheimer Pathology and Cognitive Impairment in Chinese Adults.Journal of cachexia, sarcopenia and muscle · 2025Article
- Body Circumference and Cognitive Function: Role of Apolipoprotein E ε4 in the Elderly.International journal of molecular sciences · 2025Article
- Sarcopenia and cognitive performance in hospitalized older adults: evidence of an association.Frontiers in dementia · 2025Article
- Follicle-stimulating hormone linked to cognitive decline and amyloid burden in postmenopausal women.Frontiers in aging neuroscience · 2025Article
- Development of a prediction model for cognitive impairment of sarcopenia using multimodal neuroimaging in non-demented older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Association of plasma irisin levels with amyloid burden in the Alzheimer's disease spectrum.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionDespite prior research on the association between sarcopenia and cognitive impairment in the elderly, a comprehensive model that integrates various brain pathologies is still lacking.
methodsWe used data from 528 non-demented older adults with or without sarcopenia in the Catholic Aging Brain Imaging (CABI) database, containing magnetic resonance imaging scans, positron emission tomography scans, and clinical data. We also measured three key components of sarcopenia: skeletal muscle index (SMI), hand grip strength (HGS), and the five times sit-to-stand test (5STS).
resultsAll components of sarcopenia were significantly correlated with global cognitive function, but cortical thickness and amyloid-beta (Aβ) retention had distinctive relationships with each measure. In the path model, brain atrophy resulting in cognitive impairment was mediated by Aβ retention for SMI and periventricular white matter hyperintensity for HGS, but directly affected by the 5STS. DISCUSSION: Treatments targeting each sub-domain of sarcopenia should be considered to prevent cognitive decline. HIGHLIGHTS: We identified distinct impacts of three sarcopenia measures on brain structure and Aβ. Muscle mass is mainly associated with Aβ and has an influence on the brain atrophy. Muscle strength linked with periventricular WMH and brain atrophy. Muscle function associated with cortical thinning in specific brain regions. Interventions on sarcopenia may be important to ease cognitive decline in the elderly.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.